| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | 8.82 | 4.08 | 4.57 | 3.82 | 17.28 | 7.05 |
| Quick Ratio | 8.82 | 4.08 | 4.57 | 3.82 | 17.28 | 7.05 |
| Debt / Equity | — | — | — | — | — | — |
| ROE | -70.54% | -210.23% | -120.33% | -125.47% | -38.38% | 51.61% |
| ROA | -60.22% | -145.33% | -89.02% | -86.33% | -34.70% | -40.92% |
| Asset Turnover | — | — | — | — | — | — |
| Book Value / Share | 6.30 | 0.27 | 0.83 | 1.08 | 3.83 | — |
IN8bio Inc. is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of gamma-delta T cell therapies aimed at treating cancer. Leveraging its proprietary DeltEx™ platform, the company develops innovative cell therapies employing various approaches, including allogeneic, autologous, induced pluripotent stem cell (iPSC), and genetically modified gamma-delta T cells. These specialized immune cells have unique capabilities to distinguish healthy from diseased tissue, functioning as a bridge between innate and adaptive immunity with potent antitumor activity. IN8bio’s lead candidates include INB-400 and INB-200, in clinical trials targeting glioblastoma, and INB-100, aimed at hematologic malignancies in patients undergoing bone marrow transplantation. Beyond these, its pipeline encompasses multiple preclinical and discovery-stage programs focused on solid and hematological tumors, reflecting its commitment to advancing next-generation cellular immunotherapies and striving toward the elimination of cancer.